Home › Funds › NEXTBio Capital Management LP › RYTM

NEXTBio Capital Management LP position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

NEXTBio Capital Management LP reported holding 131,758 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$12.5M, representing 5.46% of its reported portfolio and ranking #4 among its reported holdings. NEXTBio Capital Management LP has disclosed RYTM holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)131.76K sh
Reported value held$12.55M
Portfolio Weight5.46%
First reportedQ4 2025
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How NEXTBio Capital Management LP's RYTM position evolved

NEXTBio Capital Management LP first disclosed a stake in RYTM in Q4 2025 at 67,586 shares (US$7.2M). The position peaked in Q2 2026 at 131,758 shares, worth US$14.6M. Across 4 filings, NEXTBio Capital Management LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 131,758 shares valued at US$12.5M. Notable position changes include a 87% increase in Q1 2026 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 67.59K $7.23M New
Q1 2026 126.08K $10.97M Add
Q2 2026 131.76K $14.63M Add
Q3 2026 131.76K $12.55M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has NEXTBio Capital Management LP held RYTM?

NEXTBio Capital Management LP has disclosed RYTM holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is NEXTBio Capital Management LP's current position in RYTM?

As of Q3 2026, NEXTBio Capital Management LP holds 131.76K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $12.55M, representing 5.46% of its reported portfolio and ranking #4.

Has NEXTBio Capital Management LP been buying or selling RYTM?

In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in RYTM. The position peaked in Q2 2026 at 131.76K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.